Celltrion USA announced on October 5, 2026, that Omlyclo (omalizumab-igec), the first FDA-approved interchangeable biosimilar ...
In this Expert Perspectives video, Andrew Blauvelt, MD, MBA, discusses emerging efficacy data for targeted oral psoriasis therapies and how clinicians can interpret head-to-head t ...
Put your dermatology expertise to the test with Dermatology Times’ interactive quiz series.
The National Eczema Association (NEA) has released the State of AD 2026 National Indicator Report, a Milliman analysis ...
Once-daily oral icotrokinra produced sustained plaque psoriasis control through week 112, including scalp, genital, ...
Nearly 95% of assessed TikTok “glass skin” videos contained potentially misleading claims, with none citing external references and none produced by dermatologists.
Patient-reported burden improved in adults, with DLQI dropping from 14.5 to 7.9 and itch/pain numerical rating scales ...
Yassky, MD, PhD, explains how biomarkers could match patients with inflammatory skin diseases to the right therapy. Emma ...
New data presented at the 2026 European Academy of Dermatology and Venereology (EADV) Congress highlight the effects of ...
Icotrokinra (Icotyde) produced skin clearance through 2 years in patients with plaque psoriasis affecting the scalp, genitals, hands, and feet, with 70% achieving clear or almost ...
Day 2 of EADV 2026 highlighted new findings involving GLP-1–associated nail changes, long-term atopic dermatitis control, emerging therapies, alopecia, and hidradenitis suppurativa. The second day of ...
Two global randomized phase 3 studies evaluated ritlecitinib 100 mg (n=1567; exploratory 50 mg) and 50 mg (n=607; age ≥12), ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results